Merck (MRK) Advances But Underperforms Market: Key Facts
https://www.zacks.com/stock/news/2207194/merck-mrk-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2207194
Jan 08, 2024 - Merck (MRK) reachead $117.38 at the closing of the latest trading day, reflecting a +0.14% change compared to its last close.
0
The Zacks Analyst Blog Highlights Merck, Salesforce, Philip Morris International, Novartis and CME Group
https://www.zacks.com/stock/news/2206930/the-zacks-analyst-blog-highlights-merck-salesforce-philip-morris-international-novartis-and-cme-group?cid=CS-ZC-FT-press_releases-2206930
Jan 08, 2024 - Merck, Salesforce, Philip Morris International, Novartis and CME Group are part of the Zacks top Analyst Blog.
0
Top Analyst Reports for Merck, Salesforce & Philip Morris
https://www.zacks.com/commentary/2206306/top-analyst-reports-for-merck-salesforce-philip-morris?cid=CS-ZC-FT-research_daily-2206306
Jan 05, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Salesforce, Inc. (CRM) and Philip Morris International Inc. (PM).
0
Company News for Jan 3, 2024
https://www.zacks.com/stock/news/2204970/company-news-for-jan-3-2024?cid=CS-ZC-FT-corporate_summary-2204970
Jan 03, 2024 - Companies in The News Are: MRNA, RCL, NVDA, MRK
0
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024
https://www.fool.com/investing/2023/12/29/there-are-only-5-dow-stocks-i-wouldnt-buy-in-2024/?source=iedfolrf0000001
Dec 29, 2023 - There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024.
0
Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag
https://www.zacks.com/stock/news/2202226/merck-mrk-daiichi-sankyo-s-lung-cancer-adc-gets-priority-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202226
Dec 26, 2023 - Merck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024.
0
Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate
https://www.zacks.com/stock/news/2201507/pharma-stock-roundup-fda-nod-to-azn-s-eplontersen-crl-to-mrk-s-cough-candidate?cid=CS-ZC-FT-analyst_blog|stock_roundup-2201507
Dec 22, 2023 - FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.
0
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA
https://www.zacks.com/stock/news/2201156/merck-s-mrk-chronic-cough-drug-gets-another-crl-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201156
Dec 21, 2023 - Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.
0
FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab
https://www.zacks.com/stock/news/2200645/fda-accepts-merck-s-mrk-bla-for-21-valent-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200645
Dec 20, 2023 - The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.
0
Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev
https://www.zacks.com/stock/news/2200049/pfizer-pfe-stock-rises-on-fda-nod-for-expanded-use-of-padcev?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200049
Dec 19, 2023 - The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.
0